Literature DB >> 16760382

Kaposi's sarcoma-associated herpesvirus immune modulation: an overview.

S A Rahim Rezaee1, Charles Cunningham2, Andrew J Davison2, David J Blackbourn1.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the most recently discovered human herpesvirus. It is the aetiological agent of Kaposi's sarcoma (KS), a tumour frequently affecting AIDS patients not receiving treatment. KSHV is also a likely cause of two lymphoproliferative diseases: multicentric Castleman's disease and primary effusion lymphoma. The study of KSHV offers exciting challenges for understanding the mechanisms of virus pathogenesis, including those involved in establishing infection and dissemination in the host. To facilitate these processes, approximately one-quarter of KSHV genes encode cellular homologues or unique proteins that have immunomodulatory roles in cytokine production, apoptosis, cell signalling and the immunological synapse. The activities of these molecules are considered in the present review and the positions of their genes are mapped from a complete KSHV genome sequence derived from a KS biopsy. The understanding gained enables the significance of different components of the immune response in protection against KSHV infection to be evaluated. It also helps to unravel the complexities of cellular and immunological pathways and offers the potential for exploiting viral immunomodulators and derivatives in disease therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760382     DOI: 10.1099/vir.0.81919-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  58 in total

1.  Herpesvirus systematics.

Authors:  Andrew J Davison
Journal:  Vet Microbiol       Date:  2010-02-11       Impact factor: 3.293

2.  Whole-Genome Sequencing of Kaposi's Sarcoma-Associated Herpesvirus from Zambian Kaposi's Sarcoma Biopsy Specimens Reveals Unique Viral Diversity.

Authors:  Landon N Olp; Adrien Jeanniard; Clemence Marimo; John T West; Charles Wood
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

3.  KSHV infection of B-cell lymphoma using a modified KSHV BAC36 and coculturing system.

Authors:  Hyosun Cho; Hyojeung Kang
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

4.  Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.

Authors:  L M Butler; H C Jeffery; R L Wheat; H M Long; P C Rae; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

5.  Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection.

Authors:  John West; Blossom Damania
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

6.  A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKKε.

Authors:  Deguang Liang; Yuan Gao; Xianzhi Lin; Zhiheng He; Qinglan Zhao; Qiang Deng; Ke Lan
Journal:  Cell Res       Date:  2011-01-11       Impact factor: 25.617

7.  Cell-Derived Viral Genes Evolve under Stronger Purifying Selection in Rhadinoviruses.

Authors:  Amr Aswad; Aris Katzourakis
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

8.  Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies.

Authors:  Linda Mark; David G Proctor; David J Blackbourn; Anna M Blom; O Brad Spiller
Journal:  Immunology       Date:  2007-08-30       Impact factor: 7.397

9.  Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirus immunoregulatory protein.

Authors:  Cristina Aresté; Mohamed Mutocheluh; David J Blackbourn
Journal:  J Biol Chem       Date:  2009-06-24       Impact factor: 5.157

10.  The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation.

Authors:  K M Shah; S E Stewart; W Wei; C B J Woodman; J D O'Neil; C W Dawson; L S Young
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.